These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7337156)

  • 1. Modulatory effects of estrogen on immunologic responsiveness. III. Effect of hormonal versus nonhormonal therapy on tumor-associated immunity in prostatic cancer.
    Ablin RJ
    Am J Reprod Immunol (1980); 1981 Aug; 1(4):206-9. PubMed ID: 7337156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of estrogen on tumor-associated immunity in patients with adenocarcinoma of the prostate.
    Ablin RJ; Bhatti RA; Guinan PD
    Cancer Res; 1978 Nov; 38(11 Pt 1):3702-6. PubMed ID: 698929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal therapy and alterations of immunity in prostatic cancer.
    Ablin RJ
    Neoplasma; 1981; 28(3):345-50. PubMed ID: 7290262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory effects of oestrogen in prostatic cancer: update and further consideration.
    Ablin RJ
    Allergol Immunopathol (Madr); 1981; 9(1):63-70. PubMed ID: 7258047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulatory effects of oestrogen on immunological responsiveness. II. Suppression of tumour-associated immunity in patients with prostatic cancer.
    Ablin RJ; Bhatti RA; Guinan PD; Khin W
    Clin Exp Immunol; 1979 Oct; 38(1):83-91. PubMed ID: 93529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of diethylstilboesterol diphosphate on tumour-assoiciated immunity in prostatic cancer. A preliminary report.
    Bhatti RA; Ablin RJ; Guinan PD; Totonchi E; Zamora S
    Experientia; 1978 Oct; 34(10):1364-5. PubMed ID: 738427
    [No Abstract]   [Full Text] [Related]  

  • 7. Further evaluation of the effect of estrogen on tumor-associated immunity in prostatic cancer.
    Ablin RJ; Bhatti RA; Guinan PD
    Isr J Med Sci; 1979 Jan; 15(1):9-11. PubMed ID: 422345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate.
    Maatman TJ; Gupta MK; Montie JE
    J Urol; 1985 Apr; 133(4):620-1. PubMed ID: 3981712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of cellular immunologic responsiveness in the clinical management of patients with prostatic cancer. III. Inhibition of leucocyte migration.
    Ablin RJ; Marrow C; Guinan PD; Bruns GR; Sadoughi N; John T; Bush IM
    Urol Int; 1976; 31(6):444-58. PubMed ID: 1006873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer.
    Lin BJ; Chen KK; Chen MT; Chang LS
    Urology; 1994 Jun; 43(6):834-7. PubMed ID: 8197647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible suppression of host resistance by estrogen therapy for prostatic cancer.
    Ablin RJ
    Can Med Assoc J; 1976 Dec; 115(11):1082-4. PubMed ID: 1000436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist.
    Kitahara S; Yoshida K; Ishizaka K; Kageyama Y; Kawakami S; Tsujii T; Oshima H
    Endocr J; 1997 Aug; 44(4):527-32. PubMed ID: 9447285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of tumor-associated immunity by human seminal plasma and its possible role in the natural history of prostatic cancer.
    Ablin RJ; Bhatti RA; Bush IM; Guinan PD
    Eur Urol; 1980; 6(4):225-8. PubMed ID: 7389776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of estrogen on the mixed lymphocyte reaction in normal individuals and prostatic cancer patients.
    Herr HW
    Prostate; 1982; 3(1):17-21. PubMed ID: 6210901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of cellular immunologic responsiveness in the clinical management of patients with prostatic cancer. II. Effect of oestrogen, cryosurgery and transurethral resection on thymic-dependent lymphocytic blastogenesis.
    Ablin RJ; Guinan PD; Bruns GR; Sheik HI; Sadoughi N; Bush IM
    Urol Int; 1976; 31(5):383-400. PubMed ID: 1087494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of cellular immunologic responsiveness in the clinical management of patients with prostatic cancer. IV. Leucocyte adherence inhibition.
    Ablin RJ; Bhatti RA; Guinan PD; Bruns GR
    Urol Int; 1976; 31(6):459-69. PubMed ID: 795128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of giant prostate cancer].
    Fujimoto Y; Yamaha M; Maeda S; Takeuchi T; Ito Y; Kuriyama M; Ban Y; Nishiura T
    Hinyokika Kiyo; 1984 Jul; 30(7):925-30. PubMed ID: 6542303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma.
    Russo P; Liguori G; Heston WD; Huryk R; Yang CR; Fair WR; Whitmore WF; Herr HW
    Cancer Res; 1987 Nov; 47(22):5967-70. PubMed ID: 3664500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical evaluation of chemohormonal therapy as an initial treatment for stage D2 prostatic cancer--effect of UFT administration combined with hormonal therapy].
    Honda M; Takasaki E; Suzuki T; Maeda S; Imai T; Hosoya Y; Chen JA
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):105-9. PubMed ID: 7826063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.